Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia...
-
91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their...
-
Bâle, le 25 avril 2022 Le chiffre d’affaires consolidé s’inscrit en hausse de 11%1 à taux de change constants (TCC) et de 10% en francs suisses.Le chiffre d’affaires de la division Pharma...
-
Basel, 25 April 2022 Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Division sales up 6%; continued strong sales of new medicines for severe...
-
Basel, 25. April 2022 Konzernverkäufe steigen um 11%[1] zu konstanten Wechselkursen (CER) und 10% in Schweizer FrankenVerkäufe der Division Pharma wachsen um 6%; anhaltend starke Nachfrage nach...
-
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive...
-
If approved, mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat follicular lymphoma (FL) offering a new, off-the-shelf, fixed-duration treatment optionThe...
-
If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patientsSince the beginning of the pandemic, more than one million...
-
75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study 70%...
-
Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer SKYSCRAPER-02, the first randomized study of tiragolumab...